Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort

Paula Braitstein, Amy Justice, David Bangsberg, Benita Yip, Victoria Alfonso, Martin T. Schechter, Robert S. Hogg, Julio S G Montaner

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: To characterize the impact of hepatitis C (HCV) serostatus on adherence to antiretroviral treatment (ART) among HIV-infected adults initiating ART. Methods: The British Columbia HIV/AIDS Drug Treatment Program distributes, at no cost, all ART in this Canadian province. Eligible individuals used triple combination ART as their first HIV therapy and had documented HCV serology. Statistical analyses used parametric and non-parametric methods, including multivariate logistic regression. The primary outcome was ≥ 95% adherence, defined as receiving ≥ 95% of prescription refills during the first year of antiretroviral therapy. Results: There were 1186 patients eligible for analysis, including 606 (51%) positive for HCV antibody and 580 (49%) who were negative. In adjusted analyses, adherence was independently associated with HCV seropositivity [adjusted odds ratio (AOR), 0.48; 95% confidence interval (CI), 0.23-0.97; P = 0.003], higher plasma albumin levels (AOR, 1.07; 95% CI, 1.01-1.12; P = 0.002) and male gender (AOR, 2.53; 95% CI, 1.04-6.15; P = 0.017), but not with injection drug use (IDU), age or other markers of liver injury. There was no evidence of an interaction between HCV and liver injury in adjusted analyses; comparing different strata of HCV and IDU confirmed that HCV was associated with poor adherence independent of IDU. Conclusions: HCV-coinfected individuals and those with lower albumin are less likely to be adherent to their ART.

Original languageEnglish (US)
Pages (from-to)323-331
Number of pages9
JournalAIDS
Volume20
Issue number3
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Hepatitis C
Coinfection
HIV
Population
Odds Ratio
Confidence Intervals
Therapeutics
Injections
Pharmaceutical Preparations
Anti-HIV Agents
British Columbia
Hepatitis C Antibodies
Liver
Wounds and Injuries
Serology
Serum Albumin
Prescriptions
Albumins
Logistic Models
Costs and Cost Analysis

Keywords

  • Adherence
  • Antiretroviral therapy
  • Hepatitis C
  • HIV
  • Injection drug use
  • Tolerability
  • Toxicity
  • Transaminitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. / Braitstein, Paula; Justice, Amy; Bangsberg, David; Yip, Benita; Alfonso, Victoria; Schechter, Martin T.; Hogg, Robert S.; Montaner, Julio S G.

In: AIDS, Vol. 20, No. 3, 02.2006, p. 323-331.

Research output: Contribution to journalArticle

Braitstein, Paula ; Justice, Amy ; Bangsberg, David ; Yip, Benita ; Alfonso, Victoria ; Schechter, Martin T. ; Hogg, Robert S. ; Montaner, Julio S G. / Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. In: AIDS. 2006 ; Vol. 20, No. 3. pp. 323-331.
@article{2617bac5ce174768857a50c9d29ff73a,
title = "Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort",
abstract = "Objective: To characterize the impact of hepatitis C (HCV) serostatus on adherence to antiretroviral treatment (ART) among HIV-infected adults initiating ART. Methods: The British Columbia HIV/AIDS Drug Treatment Program distributes, at no cost, all ART in this Canadian province. Eligible individuals used triple combination ART as their first HIV therapy and had documented HCV serology. Statistical analyses used parametric and non-parametric methods, including multivariate logistic regression. The primary outcome was ≥ 95{\%} adherence, defined as receiving ≥ 95{\%} of prescription refills during the first year of antiretroviral therapy. Results: There were 1186 patients eligible for analysis, including 606 (51{\%}) positive for HCV antibody and 580 (49{\%}) who were negative. In adjusted analyses, adherence was independently associated with HCV seropositivity [adjusted odds ratio (AOR), 0.48; 95{\%} confidence interval (CI), 0.23-0.97; P = 0.003], higher plasma albumin levels (AOR, 1.07; 95{\%} CI, 1.01-1.12; P = 0.002) and male gender (AOR, 2.53; 95{\%} CI, 1.04-6.15; P = 0.017), but not with injection drug use (IDU), age or other markers of liver injury. There was no evidence of an interaction between HCV and liver injury in adjusted analyses; comparing different strata of HCV and IDU confirmed that HCV was associated with poor adherence independent of IDU. Conclusions: HCV-coinfected individuals and those with lower albumin are less likely to be adherent to their ART.",
keywords = "Adherence, Antiretroviral therapy, Hepatitis C, HIV, Injection drug use, Tolerability, Toxicity, Transaminitis",
author = "Paula Braitstein and Amy Justice and David Bangsberg and Benita Yip and Victoria Alfonso and Schechter, {Martin T.} and Hogg, {Robert S.} and Montaner, {Julio S G}",
year = "2006",
month = "2",
doi = "10.1097/01.aids.0000198091.70325.f4",
language = "English (US)",
volume = "20",
pages = "323--331",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort

AU - Braitstein, Paula

AU - Justice, Amy

AU - Bangsberg, David

AU - Yip, Benita

AU - Alfonso, Victoria

AU - Schechter, Martin T.

AU - Hogg, Robert S.

AU - Montaner, Julio S G

PY - 2006/2

Y1 - 2006/2

N2 - Objective: To characterize the impact of hepatitis C (HCV) serostatus on adherence to antiretroviral treatment (ART) among HIV-infected adults initiating ART. Methods: The British Columbia HIV/AIDS Drug Treatment Program distributes, at no cost, all ART in this Canadian province. Eligible individuals used triple combination ART as their first HIV therapy and had documented HCV serology. Statistical analyses used parametric and non-parametric methods, including multivariate logistic regression. The primary outcome was ≥ 95% adherence, defined as receiving ≥ 95% of prescription refills during the first year of antiretroviral therapy. Results: There were 1186 patients eligible for analysis, including 606 (51%) positive for HCV antibody and 580 (49%) who were negative. In adjusted analyses, adherence was independently associated with HCV seropositivity [adjusted odds ratio (AOR), 0.48; 95% confidence interval (CI), 0.23-0.97; P = 0.003], higher plasma albumin levels (AOR, 1.07; 95% CI, 1.01-1.12; P = 0.002) and male gender (AOR, 2.53; 95% CI, 1.04-6.15; P = 0.017), but not with injection drug use (IDU), age or other markers of liver injury. There was no evidence of an interaction between HCV and liver injury in adjusted analyses; comparing different strata of HCV and IDU confirmed that HCV was associated with poor adherence independent of IDU. Conclusions: HCV-coinfected individuals and those with lower albumin are less likely to be adherent to their ART.

AB - Objective: To characterize the impact of hepatitis C (HCV) serostatus on adherence to antiretroviral treatment (ART) among HIV-infected adults initiating ART. Methods: The British Columbia HIV/AIDS Drug Treatment Program distributes, at no cost, all ART in this Canadian province. Eligible individuals used triple combination ART as their first HIV therapy and had documented HCV serology. Statistical analyses used parametric and non-parametric methods, including multivariate logistic regression. The primary outcome was ≥ 95% adherence, defined as receiving ≥ 95% of prescription refills during the first year of antiretroviral therapy. Results: There were 1186 patients eligible for analysis, including 606 (51%) positive for HCV antibody and 580 (49%) who were negative. In adjusted analyses, adherence was independently associated with HCV seropositivity [adjusted odds ratio (AOR), 0.48; 95% confidence interval (CI), 0.23-0.97; P = 0.003], higher plasma albumin levels (AOR, 1.07; 95% CI, 1.01-1.12; P = 0.002) and male gender (AOR, 2.53; 95% CI, 1.04-6.15; P = 0.017), but not with injection drug use (IDU), age or other markers of liver injury. There was no evidence of an interaction between HCV and liver injury in adjusted analyses; comparing different strata of HCV and IDU confirmed that HCV was associated with poor adherence independent of IDU. Conclusions: HCV-coinfected individuals and those with lower albumin are less likely to be adherent to their ART.

KW - Adherence

KW - Antiretroviral therapy

KW - Hepatitis C

KW - HIV

KW - Injection drug use

KW - Tolerability

KW - Toxicity

KW - Transaminitis

UR - http://www.scopus.com/inward/record.url?scp=33645017411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645017411&partnerID=8YFLogxK

U2 - 10.1097/01.aids.0000198091.70325.f4

DO - 10.1097/01.aids.0000198091.70325.f4

M3 - Article

C2 - 16439865

AN - SCOPUS:33645017411

VL - 20

SP - 323

EP - 331

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 3

ER -